Rechercher des projets européens

28 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry (EN_ACTI2NG)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

The EN-ACTI2NG program (European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry) emanates from the recent clinical evidence that T cells expressing engineered tumor-specific immune receptors can eradicate certain tumors that do not respond to conventional treatment. To obtain T cells with reactivity to a wider array of tumors an ...
Voir le projet

 11

 TERMINÉ 

Professional cross-priming for ovary and prostate cancer (PROCROP)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

Immune responses are initiated by antigen presentation mediated by dendritic cells (DC). There is a minority subset of DC highly specialised in starting up cytotoxic T lymphocytes able to kill tumor cells. PROCROP aims to develop in three pilot clinical trials a suitable individualized cancer vaccine technology for castration resistant prostate cancer and metastatic cancer of the ovary that would ...
Voir le projet

 8

 TERMINÉ 

New experimental therapeutic approaches for Parkinson’s disease by direct DA neuronal reprogramming (REPROPARK)

Date du début: 1 juin 2014, Date de fin: 31 mai 2019,

Neurodegenerative diseases cause a significant burden on the elderly population in Europe. Parkinson’s disease (PD) affects 1.2 million people in Europe and with the increasing life expectancy this number will rise, putting more pressure on health care. Treatment of PD is only symptomatic, and therefore, there is an urgent need for more efficient therapies. Degeneration of mesencephalic DA neurons ...
Voir le projet

 2

 TERMINÉ 

Heart OMics in AGEing (HOMAGE)

Date du début: 1 févr. 2013, Date de fin: 31 janv. 2019,

As more people survive into old age, the prevalence of heart failure (HF), one of the most common and debilitating diseases in older people, will rise still further. Delaying or preventing HF will have great benefit to those at personal risk, their families, society and the economy. HOMAGE aims to provide a biomarker (BM) approach that will a) help identify i. patients at high risk of developing ...
Voir le projet

 22

 TERMINÉ 

Functional and Mecahnistic Roles of Large Intergenic Non-coding RNAs in Cancer (CANCERLINC)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2017,

Mammalian cells express thousands of RNA molecules structurally similar to protein coding genes –they are large, spliced, poly-adenylated, transcribed by RNA Pol II, with conserved promoters and exonic structures –however lack coding capacity. Although thousands exist, only few of these large intergenic non-coding RNAs (lincRNAs) have been characterized. The few that have, show powerful biological ...
Voir le projet

 1

 TERMINÉ 

Characterization of Key Epigenetic Targets in Hepatic Fibrosis and Hepatocellular Carcinoma Development. Generation of New Antifibrotic and Antitumoral Drugs. (TARGEPILIVER)

Date du début: 1 déc. 2015, Date de fin: 30 nov. 2017,

Liver fibrosis represents a common pathogenic pathway in most chronic liver diseases (CLDs) and cirrhosis, its end stage, is a huge healthcare burden. The main causes of CLD are chronic viral hepatitis B or C infection, alcohol abuse and obesity-linked steatohepatitis, conditions with increasing global incidence. Hepatocellular carcinoma (HCC) develops on this background of CLD as a multistep proc ...
Voir le projet

 1

 TERMINÉ 

Immunostimulatory Agonist antibodies for Cancer Therapy (IACT)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,

"This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system. The recent FDA-approval of Ipilimumab demonstrated that cancer immun ...
Voir le projet

 11

 TERMINÉ 

The role of miRNAs in KRAS-driven Non-Small Cell Lung Cancer (KRASmiR)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

Lung cancer is the leading cause of death by cancer in Europe. Non-small cell lung cancer (NSCLC) represents about 80% of total lung cancers. KRAS is the most commonly mutated oncogene in NSCLC, found in over 20% of patients. Since KRAS mutations are directly responsible for NSCLC, KRAS represents a relevant target to prevent NSCLC development. Yet, efforts to develop therapeutic inhibitors have f ...
Voir le projet

 1

 TERMINÉ 

The European non-coding RNA network (RNATRAIN)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

"Non-coding RNA (ncRNA) is a new research field in rapid development. It holds the potential to explain many fundamental biological phenomena and there is a vast prospective for the development of ncRNA-derived diagnostic and therapeutic tools. Hence, biotech and pharmaceutical companies are actively looking into this unexplored territory for novel targets. Therefore, there is a substantial and un ...
Voir le projet

 11

 TERMINÉ 

Targeting cardiac fibrosis for heart failure treatment (FIBRO-TARGETS)

Date du début: 1 sept. 2013, Date de fin: 31 août 2017,

The Fibro-Targets project is a multi-disciplinary 4 years program involving 10 partners ambitioning “the identification, characterisation and validation of in vitro and in vivo models of novel therapeutically relevant targets” for myocardial interstitial fibrosis (MIF) in heart failure. The project is based on the hypothesis that the intervention on novel fibrosis-related targets involved in the p ...
Voir le projet

 11

 TERMINÉ 

Supply-rate depression as endogenous anti-epileptic mechanism (ENDOGENOUS AED)

Date du début: 1 sept. 2012, Date de fin: 24 août 2017,

Epilepsy is a prevalent neurological disorder affecting more than 1 % of all people, with the estimated number of 900,000 children and adolescents suffering from active epilepsy in Europe. Most current drugs targeting this disease have important adverse side-effects. An ideal drug would, however, potentiate the endogenous anti-seizure mechanisms that keep most humans epilepsy-free.To date, these n ...
Voir le projet

 2

 TERMINÉ 

"From Brain Gene Transfer Towards Gene Therapy: Pharmacological Assessment of AAV, CAV and LVV" (BRAINVECTORS)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,

"BRAINVECTORS aims devising new gene therapy(GT)-based treatments for Parkinson’s and other neurodegenerative diseases, in substitution of current systemic treatments, by delivering neurotrophic factors (GDNF) into the CNS with new vectors derived from adeno-associated (AAV), canine adenoviruses (CAV) and lentiviruses (LV) with inducible gene expression.Although AAV, CAV and LVV are considered acc ...
Voir le projet

 12

 TERMINÉ 

Role of DNA methylation in the regulation of lincRNAs in Hematological Malignancies (LincMHeM)

Date du début: 1 sept. 2013, Date de fin: 31 août 2016,

"Traditionally, cancer researchers have focused their best efforts on studying the genetic alterations affecting the coding genes. Subsequently, it was observed that in addition to genetic alterations, epigenetic alterations affecting coding genes play an important role in tumor development. In the last decade, largely due to the ability to sequence the human genome and the observation that much o ...
Voir le projet

 1

 TERMINÉ 

The MEtabolic Road to DIAstolic Heart Failure (MEDIA)

Date du début: 1 janv. 2011, Date de fin: 30 juin 2016,

More than 50% of heart failure (HF) patients present without a major deficit of left ventricular (LV) systolic function and are presumed to suffer from diastolic HF (DHF) because diastolic LV distensibility is usually impaired in these patients. The vast majority (~80%) of DHF patients is exposed to metabolic risk factors. The MEDIA consortium therefore investigates:1) how metabolic derangements c ...
Voir le projet

 23

 TERMINÉ 

Markers for Sub-Clinical Cardiovascular Risk Assessemnt (EU-MASCARA)

Date du début: 1 déc. 2011, Date de fin: 31 mai 2016,

EU-MASCARA is a collaborative project that aims to improve diagnosis of cardiovascular diseases and prediction of cardiovascular risk by analysing a panel of biomarkers. EU-MASCARA aims to examine genetic, proteomic and metabolomic markers together with markers of inflammation, oxidative stress and cardiac remodelling to study their incremental diagnostic and predictive value over and above existi ...
Voir le projet

 16

 TERMINÉ 

Interspecies endotheliarization for organ xenotransplantation (INTEREXT)

Date du début: 1 avr. 2014, Date de fin: 12 avr. 2016,

Organ transplantation is an efficient approach or remedying end-life diseases that cannot be treated by other methods. Nevertheless, the available organs do not cover the clinical demand. As an alternative to the transplantation human organs, the xenotransplantation of animals’ organs has been proposed. Unfortunately, despite the big effort of the last decades, organs are severely rejected upon xe ...
Voir le projet

 1

 TERMINÉ 

ROLE OF THE TRANSCRIPTION FACTOR FOXP1 IN B CELL FUNCTION AND LYMPHOMAGENESIS (LYMFOXP1)

Date du début: 1 nov. 2013, Date de fin: 8 avr. 2016,

"FOXP1 (Forkhead box-P1) is a winged-helix transcription factor that has been demonstrated to be expressed in a subset of activated B-cell type (ABC) diffuse B-cell lymphomas (DLBCLs). Strong FOXP1 expression appears to have an additive adverse role in the pathogenesis and clinical behavior of ABC-DLBCL. We believe that a better understanding of the molecular impact of FOXP1 deregulation in DLBCL ...
Voir le projet

 1

 TERMINÉ 

NEW ADVANCED VACCINES IN CHRONIC HEPATITIS B (NAVICHEB)

Date du début: 1 avr. 2011, Date de fin: 31 mars 2015,

"Despite effective vaccines, hepatitis B virus (HBV) infection remains a major health problem with 2 billion people infected worldwide. Among them, 350 million are chronically infected, a major risk factor for development of hepatocellular carcinoma (HCC). A new and efficient treatment against chronic infection and HCC is strongly needed, and therefore it is important to understand HBV replication ...
Voir le projet

 1

 TERMINÉ 

The roles of juvenile NMDA receptors in synapse maturation and elimination and their association with cognition (NMDAR-synprun)

Date du début: 1 mars 2013, Date de fin: 28 févr. 2015,

The aim of the project is to understand how the NMDA receptor subunit NR3A is involved in selective synapse elimination (“pruning”) during development and how the abnormal expression of NR3A found in mental disorders such as Schizophrenia, Alzheimer´s disease and Huntington correlates with the reduction of functional synapses and deficits in the cognitive function. Importantly, the Host lab has al ...
Voir le projet

 1

 TERMINÉ 

Augmenting PBGD expression in the liver as a Novel Gene therapy for Acute Intermittent Porphyria (AIPGENE)

Date du début: 1 janv. 2011, Date de fin: 31 oct. 2014,

Acute intermittent porphyria (AIP) is a rare genetic disease in which mutations in the porphobilinogen deaminase (PBGD) gene produce insufficient activity of a protein necessary for heme synthesis. This leads to an accumulation of toxic intermediates resulting in a wide variety of problems including acute, severe abdominal pains, psychiatric and neurological disorders, and muscular weakness. Acute ...
Voir le projet

 8

 TERMINÉ 

Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis (CURELUNG)

Date du début: 1 janv. 2011, Date de fin: 30 juin 2014,

"Lung cancer (LC) is still the most lethal type of cancer worldwide. The extremely poor prognosis for LC patients is partly due to the lack of effective therapies. At present, most patients with pulmonary carcinomas are treated with chemotherapy. This essentially consists of classic cytotoxic drugs which only improve survival in small cohorts in few cases. In spite of the rapidly growing understan ...
Voir le projet

 11

 TERMINÉ 

Host and viral factors in acute hepatitis C (HEPACUTE)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2014,

Chronic hepatitis C is one of the most common chronic viral infections of humans and a major cause of chronic liver disease, cirrhosis and liver cancer. Still about 4 million new infections occur world-wide each year with 50-85% of patients progressing to chronic hepatitis C. Currently there is no marker to predict spontaneous viral clearance and to guide treatment decisions.The major objectives o ...
Voir le projet

 17

 TERMINÉ 

Evaluation of metastatic and angiogenic potential of cancer stem-like cells in distinct mouse models for lung and liver metastasis (Metastasis)

Date du début: 1 nov. 2011, Date de fin: 5 mars 2014,

Metastasis disease is the leading cause of cancer-related mortality with very few effective treatment options available for patients. Metastases are characterized by the presence of vascular proliferation, a subpopulation of stem-like cells and infiltration by various bone marrow derive cells (BMDCs). BMDCs have been shown to provide the premetastatic niches that promote the angiogenic process a ...
Voir le projet

 1

 TERMINÉ 

Restorative Plasticity At Corticostriatal Excitatory Synapses (REPLACES)

Date du début: 1 nov. 2008, Date de fin: 30 avr. 2013,

"Long-lasting, activity-dependent synaptic changes are thought to underlie the ability of the brain to translate experiences into memories and seem to represent the cellular model underlying learning and memory processes. Alteration of brain plasticity may lead to the motor and cognitive disturbances observed in neurodegenerative diseases. Therapeutic approaches targeting synaptic plasticity could ...
Voir le projet

 12

 TERMINÉ 

Longitudinal analysis to study neurodegenerative diseases mechanisms in specific neuronal subtypes (Neuronal Specificity)

Date du début: 1 mai 2009, Date de fin: 30 avr. 2013,

Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) are the most common human neurodegenerative diseases. Each features an abnormal accumulation of proteins, but whether the aggregation leads to neuronal death is controversial. HD is caused by a single mutation that increases the number of CAG repeats. Mutant huntingtin (htt) forms intraneuronal inclusion bodies (IBs). ...
Voir le projet

 1

 TERMINÉ 

NONHUMAN ADENOVIRUS VECTORS FOR GENE TRANSFER TO THE BRAIN (BrainCAV)

Date du début: 1 oct. 2008, Date de fin: 31 mars 2013,

Formidable challenges remain to prevent and treat successfully neurodegenerative diseases. Traditional pharmacological approaches, as well as those using stem cells, have made progress but their impact remain limited. As suggested by clinical results in Canavan and Parkinson’s disease, gene transfer offers substantial potential. However, this strategy of therapeutic intervention also brings unique ...
Voir le projet

 12

 TERMINÉ 

European Network for Cell Imaging and Tracking Expertise (ENCITE)

Date du début: 1 juin 2008, Date de fin: 30 nov. 2012,

"Cell therapy can be defined as the transplantation of living cells for the treatment of medical disorders. Three different principles underlie the increasing interest in cell therapy. 1. Transplanted cells used as an “active drug” 2. Transplanted cells used to replace damaged and degenerated tissue. 3. Cells used as a drug delivery vehicle. Promising results have been obtained in pre-clinical and ...
Voir le projet

 30

 TERMINÉ 

Réseau d'immunothérapie (IMMUNONET)

Date du début: 3 mars 2009, Date de fin: 30 déc. 2011,

El proyecto IMMUNONET se plantea como objetivo establecer una Red estable de investigación puntera en Inmunoterapia en el SUDOE con un Centro Virtual de apoyo donde distintos grupos de investigadores puedan cooperar y compartir recursos y equipamiento, e intercambiar información con universidades, administraciones públicas, la opinión pública en general y la iniciativa privada. Todos estos objetiv ...
Voir le projet

 9